Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Relief therapeutics Holding
Volgen
MisterBlues schreef op 16 oktober 2020 12:29 :
[...]
Ik verwacht dat het middel wel anti-virale eigenschappen heeft voor longcellen. Vandaar de redelijk resultaten bij COPD en Covid-19 onderzoeken. Zonder Hexa stelt het echter niets voor.
Dat denk ik dus ook alleen niet genoeg om een flinke virale infectie te stoppen.
Volume vandaag nog geen 3 miljoen. Iedereen staat in de wachtstand.
Check out the companies making headlines before the bell: Pfizer, BioNTech – Pfizer Chairman and CEO Albert Bourla said the vaccine candidate under development by the two drug makers could be ready for an Emergency Use Authorization application by late November. Separately, Pfizer and BioNTech are scaling up manufacturing capability for their experimental coronavirus vaccine, according to BioNTech CEO Ugur Sahin. Both companies have said they will be able to deliver the doses they’ve already agreed to provide to governments around the world, but Sahin said there will be a “struggle” to provide it more widely. Pfizer shares added 2.9% in premarket trading as of 7:30 a.m. ET.
Kleintje66 schreef op 16 oktober 2020 13:08 :
Volume vandaag nog geen 3 miljoen. Iedereen staat in de wachtstand.
We stijgen weer gestaag, gaat goed!
Gaizka1985 schreef op 16 oktober 2020 15:39 :
[...]
We stijgen weer gestaag, gaat goed!
FOMO-rally!
Volume nu ook veel hoger.
Kleintje66 schreef op 16 oktober 2020 16:02 :
Volume nu ook veel hoger.
Of zou er toch meer aan de hand zijn dan alleen FOMO? De afgelopen weken werd de koers super strak gehouden tussen een bepaalde (kleine) bandbreedte. Nu lijkt de koers ineens veel vrijer te bewegen zonder echt enorme volumes.
Het weekend komt eraan en iedereen wilt nog een stukje van de taart.. Dit weekend misschien EUA. De approval laat nog even op zich wachten waarschijnlijk, maar mag altijd dit weekend!
Bert-Jan schreef op 16 oktober 2020 16:10 :
[...]
Of zou er toch meer aan de hand zijn dan alleen FOMO? De afgelopen weken werd de koers super strak gehouden tussen een bepaalde (kleine) bandbreedte. Nu lijkt de koers ineens veel vrijer te bewegen zonder echt enorme volumes.
Tussen 0,40 en 0,60 vind ik vrij normaal in deze fase, het is dan net hoe de stemming is.
Kleintje66 schreef op 16 oktober 2020 16:50 :
[...]
Tussen 0,40 en 0,60 vind ik vrij normaal in deze fase, het is dan net hoe de stemming is.
Koers leek even uit te breken, maar is alweer vakkundig ingedamd. We houden geduld.
Fijn weekend. Er komt echt pas wat eind oktober, namelijk DSMC, dan in november FDA. Relief in een notendop: Today is Friday the 16.October 2020 and I would like to remind you of the following: We hold the patent on RLF100 and the process for its synthesis. - We show the best results of any Covid drug I have ever seen. - We block the virus from attaching to host cells in the lung AND... we prevent the cytokine storm AND... reduce inflammation! - We have already been approved by the FDA as safe. - Our intravenous RLF100 was submitted to the EUA on 17.9. - pending FDA approval. - Our clinical studies with RLF100 have reached the preliminary 102 patients on September 30th - awaiting the results. - Our clinical trial for the RLF100 treatment inhaler has been designed, submitted and is expected to be completed later this year. - Our clinical trial for the RLF100 PREVENTATIVE Inhaler has been designed, submitted and is expected to be completed next year. - We are promising for lung applications other than Covid, which also need to be investigated and tested separately. - We signed a collaboration agreement with the Institute of Arthritis and Infectious Diseases of the NIH to test RLF-100 against the influenza virus and other viruses that attack the lung. - We signed a contract with Bachem Americas to manufacture a drug substance for 1 million patients. - We signed a contract with Nephron Pharma to produce enough RLF100 for 1 million patients. - We signed a contract with the largest supplier of inhaled sterile drugs in the United States to deliver RLF-100 overnight to any U.S. hospital. - In Israel, we have received the protocol for Accompanying Care, and we are in the process of deciding how to implement this protocol. - NeuroRX's CEO, Dr. Javitt, is in the top 1% of the cited scientists worldwide, has successfully guided 7 drugs through the FDA process and has held key leadership positions under Presidents Clinton, Bush Jr., Bush Sr. and Reagan. - Robert Bestoff, Chief of Operations of NeuroRX, spent his career with Lilly & Pfizer. At Pfizer, he led the entire neuroscience and pain division and was responsible for $10 billion of their drugs. - NeuroRX's manufacturing coordinator, Rich Siegel, is the former head of Johnson & Johnson's drug portfolio. - Relief has just appointed industry veteran Jack Weinstein as CFO AND retained former CFO Jeremy Meinen as Principal Finance and Accounting Officer. - Doctor (and Congressman) Andy Harris is 1 of 3 experts on the Data Monitoring Committee. Our team is of the highest caliber. Our team is focused. We make steady, precise progress. When it's time to "go"... the world will know!
Ik vond dit wel een goeie samenvatting gepost op Yahoo: Rinaldo5 hours ago Today is Friday the 16.October 2020 and I would like to remind you of the following: We hold the patent on RLF100 and the process for its synthesis. - We show the best results of any Covid drug I have ever seen. - We block the virus from attaching to host cells in the lung AND... we prevent the cytokine storm AND... reduce inflammation! - We have already been approved by the FDA as safe. - Our intravenous RLF100 was submitted to the EUA on 17.9. - pending FDA approval. - Our clinical studies with RLF100 have reached the preliminary 102 patients on September 30th - awaiting the results. - Our clinical trial for the RLF100 treatment inhaler has been designed, submitted and is expected to be completed later this year. - Our clinical trial for the RLF100 PREVENTATIVE Inhaler has been designed, submitted and is expected to be completed next year. - We are promising for lung applications other than Covid, which also need to be investigated and tested separately. - We signed a collaboration agreement with the Institute of Arthritis and Infectious Diseases of the NIH to test RLF-100 against the influenza virus and other viruses that attack the lung. - We signed a contract with Bachem Americas to manufacture a drug substance for 1 million patients. - We signed a contract with Nephron Pharma to produce enough RLF100 for 1 million patients. - We signed a contract with the largest supplier of inhaled sterile drugs in the United States to deliver RLF-100 overnight to any U.S. hospital. - In Israel, we have received the protocol for Accompanying Care, and we are in the process of deciding how to implement this protocol. - NeuroRX's CEO, Dr. Javitt, is in the top 1% of the cited scientists worldwide, has successfully guided 7 drugs through the FDA process and has held key leadership positions under Presidents Clinton, Bush Jr., Bush Sr. and Reagan. - Robert Bestoff, Chief of Operations of NeuroRX, spent his career with Lilly & Pfizer. At Pfizer, he led the entire neuroscience and pain division and was responsible for $10 billion of their drugs. - NeuroRX's manufacturing coordinator, Rich Siegel, is the former head of Johnson & Johnson's drug portfolio. - Relief has just appointed industry veteran Jack Weinstein as CFO AND retained former CFO Jeremy Meinen as Principal Finance and Accounting Officer. - Doctor (and Congressman) Andy Harris is 1 of 3 experts on the Data Monitoring Committee. Our team is of the highest caliber. Our team is focused. We make steady, precise progress. When it's time to "go"... the world will know!
Als je dit leest kan het niet anders dan goed komen met dit aandeel :)
The opera ain't over until the fat lady sings... Goed weekend. Mvgr, Reader
Voor de liefhebbers (en handig om deze link te hebben voor later). The FDA has more than 50 regulatory pathways available to companies hoping to get a new drug or biologic approved. Here are the 22 that are most likely to be used to help bring new COVID-19 products to patients. Alexander Gaffney is the author of this piece (agaffney@agencyiq.com)agencyiq.com/the-twenty-two-regulator...
At NeuroRx, we pride ourselves on our ability to be nimble as an organization and rapidly shift our focus to areas of the utmost need. We went from concept to clinic in 10 weeks for our Critical #COVID19 study of aviptadil. Learn more about our values: neurorxpharma.com
Nog een weekje doorkabbelen of verwachten we vuurwerk deze week?
Zag dit ergens verschijnen :pbs.twimg.com/media/EkpbvyZW0AEbSg_?f... Ze lijken zich verder klaar te stomen
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee